Table 2 Quality of included trials.
From: Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
Study | Adequate sequence generation | Allocation concealment | Blinding | Incomplete outcome data addressed | Percentage who completed the trial | Free of selective reporting | Groups comparable at baseline | Sample size calculation |
|---|---|---|---|---|---|---|---|---|
Rosenstock 2009[23] | Unclear | Unclear | Yes, Double blind | Yes | Albi 30 mg QW/Albi 30 mg every two weeks/P: 71.0/75.0/78.4 | Yes | Yes | Yes |
Apovian 2010[43] | Yes | Yes | Yes, Double blind | Yes | Exe/P: 72.2/72.7 | Yes | Yes | Yes |
Bergenstal 2009[28] | Yes | Yes | No, Open label | Yes | Exe/BIAsp QD/BIAsp BID: 70.2/83.9/80.6 | Yes | Yes | Yes |
Bergenstal 2010[37] | Yes | Yes | Yes, Double blind | Yes | Exe/Sita/Pio: 79.4/86.7/79.4 | Yes | Yes | Yes |
Bunck 2009[29] | Yes | Unclear | Unclear | Yes | Exe/Glar: 83.3/90.9 | Yes | Yes | Yes |
Davies 2009 (HEELA)[30] | Yes | Unclear | No, Open label | Yes | Exe/Glar: 83.9/88.9 | Yes | Yes | Yes |
Davis 2007[31] | Unclear | Unclear | No, Open label | Yes | Exe/Ins: 57.6/93.8 | Yes | Yes | Yes |
DeFronzo 2005[42] | Unclear | Unclear | Yes, Triple blind | Yes | Exe/P: 82.3/78.8 | Yes | Yes | Yes |
DeFronzo 2010[22] | Yes | Unclear | No, Open label | Yes | Exe/Rosi: 73.3/75.6 | Yes | Yes | No |
Derosa 2010[27] | Yes | Yes | No, Single blind | Yes | Exe/Glib: 93.7/87.7 | Yes | Yes | No |
Diamant 2010[34] | Yes | Yes | No, Open label | Yes | Exe/Glar: 89.7/93.7 | Yes | Yes | Yes |
Drucker 2008[41] | Unclear | Unclear | No, Open label | Yes | Exe/Exe lar: 88.4/86.5 | Yes | Yes | Yes |
Gao 2009[45] | Yes | Yes | Yes, Double blind | Yes | Exe/P: 81.1/88.9 | Yes | Yes | Yes |
Gill 2010[26] | Unclear | Unclear | Yes, Double blind | Yes | Exe/P: 78.6/88.5 | Yes | Yes | Yes |
Heine 2005[32] | Yes | Yes | No, Open label | Yes | Exe/Glar: 80.9/90.6 | Yes | Yes | Yes |
Kadowaki 2009[20] | Unclear | Unclear | Yes, Double blind | Yes | Exe/P: 83.8/97.5 | Yes | Yes | Yes |
Kendall 2005[21] | Unclear | Unclear | Yes, Double blind | Yes | Exe/P: 82.6/76.1 | Yes | Yes | Yes |
Nauck 2007[33] | Yes | Yes | Unclear | Yes | Exe/BIAsp 30 BID: 78.7/89.9 | Yes | Yes | Yes |
Zinman 2007[67] | Yes | Yes | Yes, Double blind | Yes | Exe/P: 71.1/85.7 | Yes | Yes | Yes |
Kaku 2010[18] | Unclear | Unclear | Yes, Double blind | Yes | Lir 0.6/Lir 0.9/P: 94.3/95.5/84.1 | Yes | Yes | Unclear |
Pratley 2010[38] | Yes | Yes | No, Open label | Yes | Lir 1.2/Lir 1.8/Sita: 75.1/86.4/88.6 | Yes | Yes | Yes |
Marre 2009 (LEAD-1)[39] | Unclear | Unclear | Yes, Double blind | Yes | Lir 1.2/Lir 1.8/Rosi/P: 86.0/91.0/83.6/72.8 | Yes | Yes | Yes |
Nauck 2009 (LEAD-2)[36] | Yes | Yes | Yes, Double blind | Yes | Lir 1.2/Lir 1.8/Glim/P: 82.1/78.9/86.8/61.2 | Yes | Yes | Yes |
Zinman 2009 (LEAD-4)[44] | Yes | Yes | Yes, Double blind | Yes | Lir 1.2/Lir 1.8/P: 86.0/74.7/68.4 | Yes | Yes | Yes |
Russell-Jones 2009 (LEAD-5)[35] | Yes | Yes | Unclear | Yes | Lir 1.8/Glar/P: 90.0/94.4/84.2 | Yes | Yes | Yes |
Buse 2009 (LEAD-6)[40] | Unclear | Yes | No, Open label | Yes | Lir 1.8/Exe: 86.7/81.0 | Yes | Yes | Yes |
Nauck 2009[24] | Yes | Yes | Yes, Double blind | Yes | Tas 10 mg QW/Tas 20 mg QW/Tas 20 mg every two weeks/P: 91.8/88.0/93.9/95.9 | Yes | Yes | Yes |
Ratner 2010[25] | Yes | Unclear | Yes, Double blind | Yes | Tas 20 mg QW/Tas 30 mg QW/Tas 40 mg QW: 90.6/81.8/81.3/96.9 | Yes | Yes | No |